Last updated: July 27, 2026
Desogestrel/ethinyl estradiol (DSG/EE) is an established combined oral contraceptive (COC) with broad global availability, limited patent-driven exclusivity in most markets, and low incremental clinical-trial churn relative to new molecular entities. Near-term strategy is driven by (1) regulatory lifecycle management (label updates, dosing regimens, and product-line extensions), (2) switching to optimized formulations (if any), and (3) competitive pressure from low-cost generics. Commercial upside is concentrated in developed markets where brand persistence and formulary placement matter, and in select geographies where supply constraints or pricing differentials sustain margins.
Because DSG/EE is a widely marketed, mature active ingredient combination, this update focuses on actionable program status and market dynamics. However, no specific clinical trial dataset, FDA product status, or patent/Orange Book listing set was provided, so a complete, citation-backed “clinical trials update” and “projection” cannot be generated from verifiable inputs.
What clinical trials are currently recruiting or ongoing for desogestrel plus ethinyl estradiol?
No sufficient trial-level source material was included to produce a complete and accurate status table for current recruiting, active, completed, or terminated studies tied to DSG/EE.
Are there phase 3 or phase 4 studies for desogestrel/ethinyl estradiol?
A DSG/EE-specific phase map cannot be compiled without a trial registry extraction (e.g., ClinicalTrials.gov or equivalent) for active ingredients, formulations, and sponsor assignments.
What endpoints do desogestrel/ethinyl estradiol studies measure (contraception efficacy, bleeding, safety)?
A structured endpoints overview cannot be confirmed for current studies without access to protocol abstracts and results fields.
What is the market size and revenue forecast for desogestrel/ethinyl estradiol combined oral contraceptives?
No market baseline (sales by geography, formulation, or brand vs generic split) or any cited forecast source was provided. A “projection” would be ungrounded without at least one anchored dataset (e.g., IQVIA estimates, payer claims, or company-reported sales).
Where is demand strongest for desogestrel/ethinyl estradiol (US, EU, LATAM, APAC)?
A geography-specific outlook cannot be produced without regional sales inputs or distributions of listed products per market.
What pricing dynamics apply to desogestrel/ethinyl estradiol in 2025–2029?
Price and margin expectations require (1) current WAC/AWP spreads, (2) generic penetration by NDC/strength, and (3) reimbursement/PA rules. None were provided.
Does desogestrel/ethinyl estradiol compete mainly with ethinyl estradiol/levonorgestrel and other COCs?
A cross-molecule share comparison requires current market share or formulary utilization data by active ingredient. No dataset was supplied.
How many brands and generic versions of desogestrel plus ethinyl estradiol exist, and what does that imply for competitive intensity?
A count of available products (US NDCs, EU MAHs, global SKUs) cannot be validated without a product inventory source.
How fragmented is the market across strengths and regimens (21/7, 24/4, continuous/extended)?
Regimen-level fragmentation requires regimen-specific product listings and prescribing patterns, not provided.
What manufacturing and supply-chain risks affect availability?
Supply risk assessments need manufacturer roster and production footprint data by region, which were not provided.
When does desogestrel/ethinyl estradiol lose exclusivity in key markets?
No exclusivity chronology can be produced without:
- specific branded product identifiers (name, strength, dosage form),
- Orange Book entries (US), EU SPC registers (if any), and
- local patent/application files.
What patent landscape protects desogestrel/ethinyl estradiol in the US?
Patent coverage for DSG/EE depends on specific brand formulations and method-of-use claims; without branded references and patent numbers, a correct estate map cannot be created.
Do method-of-use patents exist for desogestrel/ethinyl estradiol (ACNE, endometriosis, menstrual disorders)?
Method-of-use coverage cannot be stated without a claim-by-claim dataset tied to DSG/EE products.
What is the Orange Book status of desogestrel plus ethinyl estradiol and what generic entry risks exist?
No Orange Book status or listing set was provided. A generic entry risk evaluation requires:
- relevant branded NDA/ANDA pairs,
- listed patents with expiration dates,
- exclusivity codes and dates, and
- any Paragraph IV litigations.
What FDA regulatory pathway applies to generic desogestrel/ethinyl estradiol tablets?
No NDA/ANDA pathway mapping was supplied. A correct pathway statement depends on whether the reference product is an NDA with listed patents, whether there are multiple RLDs, and whether the generic is submitted as ANDA with bioequivalence waivers or requires additional bridging.
Which companies dominate manufacturing and distribution of desogestrel plus ethinyl estradiol in 2025?
No manufacturer list, distributor roster, or market-share dataset was included, so domination claims cannot be made.
How does desogestrel plus ethinyl estradiol compare with levonorgestrel plus ethinyl estradiol and drospirenone COCs on safety and adoption?
A comparative analysis cannot be produced without:
- current comparative utilization data,
- guideline text referencing DSG/EE positioning,
- and quantified safety outcomes from relevant trials or pharmacovigilance studies.
What patent litigation affects desogestrel/ethinyl estradiol and how do settlements shape launch timing?
No litigation docket, court filings, or settlement facts were provided. DSG/EE litigation patterns are product-specific; without named defendants/plaintiffs and patent numbers, accuracy is not possible.
Key Takeaways
- Desogestrel/ethinyl estradiol is a mature COC with generally low incremental clinical development intensity and high competitive pressure from generics.
- A reliable “clinical trials update” and “market projection” require anchored, product- and geography-specific sources that were not included in the input.
- Action planning for DSG/EE in 2026–2029 should prioritize regulatory lifecycle and commercial execution (portfolio, pricing, formulary access) more than new clinical evidence generation.
FAQs
- What are the most common desogestrel/ethinyl estradiol dosing regimens prescribed globally?
- How does generic substitution affect total demand for desogestrel/ethinyl estradiol?
- What real-world bleeding-profile differences drive switching among COCs containing desogestrel and ethinyl estradiol?
- Do thrombosis risk communications differ for desogestrel/ethinyl estradiol versus levonorgestrel/ethinyl estradiol COCs?
- What regulatory label updates have occurred recently for desogestrel plus ethinyl estradiol products?
References
No sources were provided in the prompt, and no verifiable citations can be generated.
